New scan could reveal hidden danger in aortic aneurysms
NCT ID NCT07548099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new imaging drug called 64Cu-DOTA-ECL1i to see if it can show inflammation in the wall of the aorta in people with abdominal aortic aneurysms. About 30 adults with aneurysms and some without will get a PET/CT scan after receiving the drug. The goal is to understand how inflammation relates to aneurysm growth and how consistent the scans are over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL AORTIC ANEURYSM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Penn Medicine; Perelman School of Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves replace CT scans for aortic aneurysm monitoring?
- Can a stent-graft keep aortic aneurysms in check for years? a long-term follow-up study aims to find out.
- Aneurysm repair may stiffen arteries — a study asks what that means for the heart
- Rehab after aneurysm surgery: could a 3-Week program boost heart and lung fitness?
- Nerve block may offer safer pain relief after major aortic surgery
- New device aims to seal aortic aneurysms without open surgery